featured
Perspectives on First-Line RCC Treatment Following the CheckMate Trial
Interview by
Interview with
Interview with
Interview with
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Escudier BJ, Motzer RJ, Sharma P, et al Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 4509.
- Choueiri TK, Escudier B, Powles T, et al. Cabozantinib Versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results From a Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2016;17(7):917-927.
- Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-1823.
Disclosure statements are available on the authors' profiles:
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.